Roloff, G., Faramand, R., Aldoss, I., Kopmar, N. E., Schwartz, M., Dekker, S. E., … Muffly, L. S. (2023). Outcomes following brexucabtagene autoleucel administered as an FDA-approved therapy for adults with relapsed/refractory B-ALL. In JOURNAL OF CLINICAL ONCOLOGY (Vol. 41).

Roloff, Gregory, Rawan Faramand, Ibrahim Aldoss, Noam Edward Kopmar, Marc Schwartz, Simone E. Dekker, Chenyu Lin, et al. “Outcomes following brexucabtagene autoleucel administered as an FDA-approved therapy for adults with relapsed/refractory B-ALL.” In JOURNAL OF CLINICAL ONCOLOGY, Vol. 41, 2023.

Roloff G, Faramand R, Aldoss I, Kopmar NE, Schwartz M, Dekker SE, et al. Outcomes following brexucabtagene autoleucel administered as an FDA-approved therapy for adults with relapsed/refractory B-ALL. In: JOURNAL OF CLINICAL ONCOLOGY. 2023.

Roloff, Gregory, et al. “Outcomes following brexucabtagene autoleucel administered as an FDA-approved therapy for adults with relapsed/refractory B-ALL.” JOURNAL OF CLINICAL ONCOLOGY, vol. 41, no. 16, 2023.

Roloff G, Faramand R, Aldoss I, Kopmar NE, Schwartz M, Dekker SE, Lin C, Tracy S, Vilchez SM, Dykes K, O’Connor T, Ahmed MA, Gupta VK, Ladha A, Tsai S, Leonard JT, Galal A, Cassaday RD, Shah BD, Muffly LS. Outcomes following brexucabtagene autoleucel administered as an FDA-approved therapy for adults with relapsed/refractory B-ALL. JOURNAL OF CLINICAL ONCOLOGY. 2023.